Search results
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that ...
Biogen is an Equal Employment Opportunity and Affirmative Action employer. All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law.
Biogen | 995,316 followers on LinkedIn. Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to ...
Grow Your Career. At Biogen, we value every employee’s unique career goals. It’s our priority to focus on you as you build a rewarding, lasting career that develops your potential, enriches your professional experience and continues to inspire you to care deeply, work fearlessly and change lives.
May 30, 2024. Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS. May 30, 2024. Biogen to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference. May 26, 2024. “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South ...
About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Biogen. Science & Innovation. We work in disease areas with some of the greatest unmet need. We work relentlessly, knowing that bold new possibilities await discovery. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments. Learn more.
